A detailed history of Lord, Abbett & Co. LLC transactions in Argenx Se stock. As of the latest transaction made, Lord, Abbett & Co. LLC holds 162,963 shares of ARGX stock, worth $97 Million. This represents 0.29% of its overall portfolio holdings.

Number of Shares
162,963
Holding current value
$97 Million
% of portfolio
0.29%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$434.22 - $551.9 $70.8 Million - $89.9 Million
162,963 New
162,963 $88.3 Million
Q3 2023

Oct 07, 2024

BUY
$369.35 - $548.43 $50.6 Million - $75.1 Million
137,016 Added 76.39%
316,380 $156 Million
Q3 2023

Nov 13, 2023

BUY
$369.35 - $548.43 $50.6 Million - $75.1 Million
137,016 Added 76.39%
316,380 $156 Million
Q2 2023

Oct 07, 2024

BUY
$360.14 - $422.58 $17.2 Million - $20.1 Million
47,671 Added 36.2%
179,364 $69.9 Million
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $17.2 Million - $20.1 Million
47,671 Added 36.2%
179,364 $69.9 Million
Q1 2023

Oct 07, 2024

SELL
$334.23 - $403.65 $4.44 Million - $5.37 Million
-13,292 Reduced 9.17%
131,693 $49.1 Million
Q1 2023

May 12, 2023

SELL
$334.23 - $403.65 $4.44 Million - $5.37 Million
-13,292 Reduced 9.17%
131,693 $49.1 Million
Q4 2022

Oct 07, 2024

BUY
$342.17 - $402.31 $49.6 Million - $58.3 Million
144,985 New
144,985 $54.9 Million
Q4 2022

Feb 10, 2023

SELL
$342.17 - $402.31 $79 Million - $92.9 Million
-230,850 Reduced 61.42%
144,985 $54.9 Million
Q3 2022

Nov 14, 2022

BUY
$343.2 - $395.75 $28.5 Million - $32.9 Million
83,084 Added 28.38%
375,835 $133 Million
Q2 2022

Aug 12, 2022

BUY
$269.58 - $378.88 $71.6 Million - $101 Million
265,768 Added 984.95%
292,751 $111 Million
Q1 2022

May 13, 2022

BUY
$254.45 - $351.06 $470,223 - $648,758
1,848 Added 7.35%
26,983 $8.51 Million
Q4 2021

Feb 11, 2022

BUY
$272.01 - $353.03 $673,224 - $873,749
2,475 Added 10.92%
25,135 $8.8 Million
Q3 2021

Nov 09, 2021

BUY
$295.0 - $350.58 $326,270 - $387,741
1,106 Added 5.13%
22,660 $6.84 Million
Q2 2021

Aug 11, 2021

BUY
$257.11 - $319.92 $1.12 Million - $1.4 Million
4,362 Added 25.37%
21,554 $6.49 Million
Q1 2021

May 11, 2021

SELL
$268.3 - $380.31 $55.1 Million - $78 Million
-205,201 Reduced 92.27%
17,192 $4.74 Million
Q4 2020

Feb 09, 2021

BUY
$248.13 - $308.36 $90,071 - $111,934
363 Added 0.16%
222,393 $65.4 Million
Q3 2020

Nov 12, 2020

SELL
$215.51 - $272.51 $13.6 Million - $17.2 Million
-62,957 Reduced 22.09%
222,030 $58.3 Million
Q2 2020

Aug 14, 2020

SELL
$127.44 - $232.72 $6.5 Million - $11.9 Million
-51,040 Reduced 15.19%
284,987 $64.2 Million
Q1 2020

May 14, 2020

BUY
$108.83 - $165.23 $14.7 Million - $22.3 Million
135,008 Added 67.16%
336,027 $44.3 Million
Q4 2019

Feb 14, 2020

SELL
$106.59 - $164.21 $2.36 Million - $3.63 Million
-22,122 Reduced 9.91%
201,019 $32.3 Million
Q3 2019

Nov 14, 2019

SELL
$113.31 - $150.51 $53.8 Million - $71.5 Million
-475,026 Reduced 68.04%
223,141 $25.4 Million
Q2 2019

Aug 14, 2019

BUY
$115.0 - $141.58 $5.9 Million - $7.26 Million
51,290 Added 7.93%
698,167 $98.8 Million
Q1 2019

May 15, 2019

BUY
$98.85 - $134.59 $45.7 Million - $62.3 Million
462,607 Added 251.05%
646,877 $80.8 Million
Q4 2018

Feb 14, 2019

BUY
$63.81 - $109.82 $11.8 Million - $20.2 Million
184,270 New
184,270 $17.7 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $32.9B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Lord, Abbett & Co. LLC Portfolio

Follow Lord, Abbett & Co. LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lord, Abbett & Co. LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lord, Abbett & Co. LLC with notifications on news.